Could growth hormone ease stubborn stomach paralysis?

NCT ID NCT06803589

Recruiting now Symptom relief Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early study tests whether a weekly shot of low-dose growth hormone can improve symptoms like nausea, fullness, and belly pain in people with gastroparesis (stomach paralysis) that hasn't responded to standard treatments. Ten adults will receive the drug for 12 weeks, and researchers will track symptom changes using a standard questionnaire. Because this is a very small, early-phase trial, the main goal is to see if the approach is worth studying further.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: growth hormone (somapacitan-beco, Sogroya)
What this could lead to: If it works, this could point toward a new way to manage stubborn gastroparesis symptoms without major side effects.
What could go wrong: This is a very early, tiny trial with only 10 people, so results may not apply widely. Growth hormone can have risks like joint pain or fluid retention, and it is not a cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROPARESIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastroparesis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTROPARESIS

Contacts and locations

Locations

Mayo Clinic
RECRUITING

Phoenix, Arizona, 85054, United States
Mayo Clinic in Arizona
RECRUITING

Scottsdale, Arizona, 85259, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.